Home Contact
Products
New Innovations
Research
Meetings & Publications
> Interventional Cardiology
> Vascular Surgery
> Peripheral Interventions
> Stent Coating Machine > Yukon DES > Yukon Plus > Curare Cathy No 3
The Stent Coating Machine
> Product Overview > The Concept > Features > Handling
  1. THE NUMBER OF DRUGS AVAILABLE IS STILL LIMITED (SIROLIMUS; PACLITAXEL) – although many other drugs have been successfully tested, time-to-market is very long, which is a serious barrier to introducing new drugs in clinical use.
  2. FOR THE FIRST TIME THERE IS A POSSIBILITY OF A FREE CHOICE OF DRUG AT THE TIME OF IMPLANTATION - That means that the treatment can be adapted to the individual patient and the drug can be chosen according to the individual needs.
    Sirolimus and Taxol both are very aggressive cytostatic drugs and might not be suitable for all types of lesions. The machine might offer the possibility to choose less aggressive drugs for less complex lesions and vice versa. This might also be true for different very complex patient cohorts such as diabetic patients and patients on dialysis, in whom still a lot of research is needed. Latest publications have shown that e.g. insulin – dependent diabetics seem not to respond to Sirolimus as well as other patients. By the use of the machine intense research in this field is possible and reaction to latest scientific findings can be performed. Nevertheless Sirolimus remains a possibility to be used with the Translumina technology but can be dosed according to the lesion.
  3. UP TO NOW RESULTS HAVE BEEN INFLUENCED BY MORE THAN ONE FACTOR – AS THE RESTENOSIS QUALITIES OF THE STENT PLATFORM AS WELL AS OF THE DRUG WERE INFLUENCING THE FINAL RESULT. In the case of the translumina system the delivery platform is always the same (YUKON DES), and the pure effect of different drugs can be investigated. They can therefore for the first time be compared without bias. After going a little bit more into detail about the complex issue of polymers and topcoatings the fact that the drug is offered in its pure form without polymer is of an advantage. The top coating is not necessary, as it serves primarily conservation purposes.
  4. THE COATING PROCESS ITSELF TAKES ONLY 3 – 7 MINUTES AND GIVES NO DELAY IN THE CLINICAL ROUTINE. CAN BE PERFORMED BY NURSE OR AN ASISSTANT COLLEAGUE.
  5. PRICE - as the drug is supplied by the hospital itself, Translumina as a company is not obliged to price negotiations with the different drug companies and can therefore offer a quite substantial price benefit when compared to other stent companies.
  6. STORAGE IS NOT AN ISSUE - whereas the “conventional” DES systems can only be stored between 3 – 6 months, the Translumina stent platform can be stored for up to 2 years without expiring. Although of course the patient’s benefit is always the main goal, this side aspect becomes more and more important.7. FUTURE OUTLOOK: Human growth factors and different uses of gene therapy have also been a hot topic in Cardiology for the last years. This machine offers possibly the first modality to apply these factors on a stent. In the conventional approach sterilization of the stent has to be performed after application of the drug/organic material. Therefore these highly sensible factors would be destroyed by the sterilization process. By the use of the machine everything, be it cells, growth factors etc. can be applied to the stent surface, as no conservation or sterilization is needed afterwards.
Links to
British Cardiovascular Intervention Society
The Vascular Society
The BCIA

Related Information
FAQ
Advantages
Polymer Issues
© 2004 Kiwimed | Appono Production